Kymera Therapeutics Announces Third Quarter 2025 Financial Results and Provides a Business Update GlobeNewswire November 04, 2025 Enrollment and dosing completed in KT-621 (STAT6) BroADen Phase 1b trial in atopic dermatitis (AD) patients, with data to be reported in December 2025 Initiated KT-621 BROADEN2 Phase 2b trial in AD KT-621 BREADTH Phase 2b trial in […]

Maze Therapeutics to Participate in Four Upcoming Investor Conferences GlobeNewswire November 04, 2025 SOUTH SAN FRANCISCO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) — Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced that company management will participate in four upcoming investor

Madrigal Pharmaceuticals Reports Third-Quarter 2025 Financial Results and Provides Corporate Updates GlobeNewswire November 04, 2025 Third-quarter 2025 Rezdiffra(TM) (resmetirom) net sales of $287.3 million As of September 30, 2025, more than 29,500 patients on Rezdiffra Closed global licensing agreement with CSPC Pharma to add oral GLP-1 to pipeline New Orange Book listed patent for Rezdiffra

AmpliTech Group To Release Q3 – 2025 Earnings On November 14th Before Market Opening – Also Announces Investor's Conference Call GlobeNewswire November 04, 2025 HAUPPAUGE, N.Y., Nov. 04, 2025 (GLOBE NEWSWIRE) — AmpliTech Group, Inc (Nasdaq: AMPG, AMPGW), a designer, developer, and manufacturer of state-of-the-art signal processing components for satellite, Public and Private ORAN 5G,

Abcourt Announces Arrangements for Upcoming Annual Meeting of Shareholders in Event of Canada Post Service Disruption GlobeNewswire November 04, 2025 ROUYN-NORANDA, Quebec, Nov. 04, 2025 (GLOBE NEWSWIRE) — Abcourt Mines Inc. (TSXV: ABI) (OTCQB: ABMBF) (“Abcourt” or the “Corporation“) wishes to update its shareholders regarding the Corporation's upcoming annual meeting, which is to be held

Pacira BioSciences Enters Exclusive License Agreement with AmacaThera for its Novel Long-acting Analgesic for Postsurgical Pain Control GlobeNewswire November 04, 2025 — Advances 5×30 strategy by expanding pipeline with a highly complementary asset that has the potential to provide several days of pain control — — Phase 2 program for AMT-143 expected to begin in

Propanc Biopharma, Inc. Pursues Strategic Acquisition Plan Targeting Digital Asset Treasury (DAT) Companies Trading Below Market Cap to Net Asset Value (MNAV) GlobeNewswire November 04, 2025 MELBOURNE, Australia, Nov. 04, 2025 (GLOBE NEWSWIRE) — Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing new treatments for patients suffering from recurrent and

OTC Markets Group Welcomes First Reliance Bancshares, Inc. to OTCQX GlobeNewswire November 04, 2025 NEW YORK, Nov. 04, 2025 (GLOBE NEWSWIRE) — OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced First Reliance Bancshares, Inc. (OTCQX: FSRL), the holding company for First Reliance Bank, has

Ocular Therapeutix(TM) Achieves Target Randomization of 555 Subjects in SOL-R GlobeNewswire November 04, 2025 SOL-R, the second registrational trial of AXPAXLI(TM) in wet AMD, remains on track for topline data in 1H 2027 Together with SOL-1, these complementary trials are expected to form the basis of a potential NDA submission for AXPAXLI in wet AMD

LGI Homes, Inc. Reports Third Quarter 2025 Results GlobeNewswire November 04, 2025 THE WOODLANDS, Texas, Nov. 04, 2025 (GLOBE NEWSWIRE) — LGI Homes, Inc. (NASDAQ: LGIH) today announced financial results for the third quarter and the nine months ended September 30, 2025. “We are pleased with our third quarter results, which met our stated guidance